NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02<
26 Feb 2025

Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02

Proceeds will be used to support the advancement of multiple first-in-class ADC programs into the clinic and through clinical proof of concept
Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy<
20 Feb 2025

Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy

The Phase 3 EPIC trial is a randomized, sham-controlled, double-blind study evaluating NRTX-1001 cell therapy in adults with drug-resistant mesial temporal lobe epilepsy
NorthSea Therapeutics Announces Expansion of Leadership Team with Key Industry Veteran Hires<
20 Feb 2025

NorthSea Therapeutics Announces Expansion of Leadership Team with Key Industry Veteran Hires

Topline data from SEFA-1024 Phase 2a clinical trial in SHTG expected in 3Q 2025
Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types<
19 Feb 2025

Ona Therapeutics Strengthens Leadership Team to Accelerate First-in-Class ADCs into Clinical Development Across Cancer Types

Accelerating development of first-in-class ADCs in multiple large solid tumor types designed against novel targets with a focus on eliminating hard-to-treat resistant cancer cells
Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria<
04 Feb 2025

Mineralys Therapeutics Completes Enrollment in Explore-CKD Phase 2 Trial of Lorundrostat for the Treatment of Hypertension in Subjects with Stage 2 to 3b CKD and Albuminuria

Continues to anticipate announcing topline data from Explore-CKD trial in Q2 2025
SparingVision advances PRODYGY trial into Phase II following positive DSMB recommendation<
21 Jan 2025

SparingVision advances PRODYGY trial into Phase II following positive DSMB recommendation

DSMB confirms favorable safety profile of SPVN06 across all three doses in patients with severe advanced rod-cone dystrophy (RCD)(n=9)
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers<
10 Jan 2025

LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

Initial Phase 1 data read-out expected by year-end 2025
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension<
08 Jan 2025

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension

Estimated 54 million people suffer from obstructive sleep apnea in the U.S.

Anaconda Biomed Appoints Trent Reutiman New CEO<
07 Jan 2025

Anaconda Biomed Appoints Trent Reutiman New CEO

Seasoned Medtech Executive to Expand Company Presence Into U.S.
Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval<
07 Jan 2025

Xeltis announces completion of enrolment in EU Pivotal Trial for aXess and prepares for market approval

Primary endpoint readouts anticipated in Q2 2025, first market approval expected in 2026

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.